Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Beam Therapeutics (BEAM) and Glaukos (GKOS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Rhythm Pharmaceuticals (RYTM – Research Report), Beam Therapeutics (BEAM – Research Report) and Glaukos (GKOS – Research Report) with bullish sentiments.

Rhythm Pharmaceuticals (RYTM)

Wells Fargo analyst Derek Archila maintained a Buy rating on Rhythm Pharmaceuticals today and set a price target of $53.00. The company’s shares closed last Monday at $39.65.

According to TipRanks.com, Archila is a 4-star analyst with an average return of 8.2% and a 44.2% success rate. Archila covers the Healthcare sector, focusing on stocks such as Zentalis Pharmaceuticals, Apellis Pharmaceuticals, and Arvinas Holding Company.

Rhythm Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $56.43.

See the top stocks recommended by analysts >>

Beam Therapeutics (BEAM)

J.P. Morgan analyst Eric Joseph maintained a Buy rating on Beam Therapeutics today and set a price target of $44.00. The company’s shares closed last Monday at $33.69.

According to TipRanks.com, Joseph is a 4-star analyst with an average return of 6.0% and a 51.8% success rate. Joseph covers the Healthcare sector, focusing on stocks such as Monte Rosa Therapeutics, Enanta Pharmaceuticals, and Rocket Pharmaceuticals.

Beam Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $54.00.

Glaukos (GKOS)

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Glaukos, with a price target of $103.00. The company’s shares closed last Monday at $88.72, close to its 52-week high of $97.24.

According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of 11.4% and a 62.1% success rate. Biegelsen covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, GE Healthcare Technologies Inc, and Bausch + Lomb Corporation.

Currently, the analyst consensus on Glaukos is a Strong Buy with an average price target of $105.13, which is a 18.5% upside from current levels. In a report released yesterday, Citi also maintained a Buy rating on the stock with a $120.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on RYTM:

• Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
• Rhythm Pharmaceuticals Announces New Employment Inducement Grants
• Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
• 3 Best Stocks to Buy Now, 2/23/2024, According to Top Analysts 
• Stifel ups Rhythm Pharmaceuticals target, calls pullback buying opportunity